CytoSorbents is a critical care immunotherapy company commercializing its CE approved CytoSorb, a safe and effective cytokine adsorber. CytoSorb is designed to attenuate the dysregulated, hyperinflammatory response („cytokine storm“) present in septic shock and other, non-infectious systemic hyperinflammatory states by reducing elevated levels of cytokines and other inflammatory mediators. This modulation of the immune response can lead to an improvement of hemodynamics, a reduction in the need for vasopressors and overall to an increased chance for recovery of organ functions and improved patient outcomes. CytoSorb is indicated in various hyperinflammatory states of infectious and non-infectious origin, e.g. after cardiac surgery, in cardiogenic shock, trauma, burns, pancreatitis and infection. So far it has been used safely and well tolerated in more than 27,000 single treatments worldwide. CytoSorb Therapy – REGAIN CONTROL!


Partner type

This partner supported the following IFAD meetings:

  • IFAD 2015
  • IFAD 2017
  • IFAD 2018
  • IFAD 2020

Share on Social Media

Our Diamond Partners

Become a partner too!

Social Media

  like us on Facebook

  follow us on Twitter

  join Discussion group

  join us on Linkedin

  newsletter sign up

  post on the blog